What component is added to an ICS and LABA to create triple therapy preventers?
Answer
Long-Acting Muscarinic Antagonist (LAMA)
Triple therapy inhalers represent a more complex formulation of preventer medications designed for patients whose asthma remains inadequately controlled even when using dual ICS/LABA combinations. To achieve this triple mechanism of action in a single device, a Long-Acting Muscarinic Antagonist (LAMA) is incorporated alongside the standard Inhaled Corticosteroid (ICS) and the Long-Acting Beta Agonist (LABA). Examples of these complex preventers include Trelegy Ellipta, which features Fluticasone Furoate (ICS), Umeclidinium (LAMA), and Vilanterol (LABA), leveraging three different pathways to maximize airway opening and inflammation control.
Related Questions
What is the primary function of preventers or controllers in asthma management?Which medication class forms the cornerstone of long-term asthma control?For combination inhalers, why must LABAs be paired with a corticosteroid?Which brand name corresponds to the ICS medication Ciclesonide?What component is added to an ICS and LABA to create triple therapy preventers?How do Leukotriene Modifiers, like Montelukast, work to prevent asthma symptoms?Which combination inhaler is approved for the Single Maintenance And Reliever Therapy (SMART) protocol?What specific driver of inflammation does Omalizumab (Xolair) primarily target?Why might a patient prefer a dry powder device like Ellipta over an Advair MDI requiring a spacer?What did one review state about the strength of a particular Fluticasone HFA formulation?